1 citations
,
February 2022 in “The Journal of Urology” This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.
1 citations
,
February 2022 in “JAMA Dermatology” This abstract provides no research findings; it is just information about the JAMA Dermatology journal's website and access options.
1 citations
,
December 2021 in “Natural Product Research” In this study, in silico screening and molecular simulations identified β-sitosterol and brassicasterol as stable potential inhibitors of 5α-reductase1, suggesting they could be explored for androgenic alopecia treatment.
1 citations
,
June 2021 in “Singapore Medical Journal” This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.
1 citations
,
March 2021 in “F1000Research” This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.
1 citations
,
October 2019 in “مجله كليه طب الكندي” In this study, researchers highlight the role of androgens like dihydrotestosterone in the pathophysiology of acne, pointing to the enzyme 5a-reductase type 1 as potentially more active in individuals with acne, which may contribute to hormonal influences in the condition's development.
1 citations
,
April 2019 in “Clinical Breast Cancer” This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.
1 citations
,
January 2019 in “Journal of the Egyptian Women's Dermatologic Society (Print)” This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.
1 citations
,
August 2017 in “The Journal of urology/The journal of urology” 5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.
1 citations
,
March 2017 in “Journal of evolution of medical and dental sciences” This study compared microneedling combined with platelet-rich plasma and microneedling with minoxidil for treating androgenetic alopecia in men, finding both approaches effectively improved hair density and alopecia grade.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
1 citations
,
November 2015 in “Cochrane library” This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.
1 citations
,
January 2015 in “Journal of Clinical Toxicology” In this study, paternal exposure to finasteride prior to or during pregnancy was linked to a majority of normal full-term births, although some cases resulted in abortions, aligning with previous animal study findings.
1 citations
,
January 2014 in “Journal of Dermatology and Venereology” In this study, a plant extract from Northeastern Turkey demonstrated potential for preventing hair loss by downregulating inflammation and androgen production and promoting hair growth in HaCaT cell models.
1 citations
,
October 2013 in “Our Dermatology Online” This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.
1 citations
,
January 2012 in “Daehan namseong gwahag hoeji” This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.
1 citations
,
January 2002 in “PubMed” The researchers reported that both finasteride and PM-9 competitively inhibit the 5 alpha-reductase enzyme in P. crustosum broth.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.
1 citations
,
November 1995 in “Postgraduate medical journal” This article presents a case of 5-alpha-reductase deficiency in a Saudi individual, reporting no new research findings.
July 2026 in “Postgraduate Medicine” Results are not reported in this commentary, but it discusses the influence of different control group choices—an active-comparator versus non-drug users—on measuring depression risk in studies of 5-alpha reductase inhibitors.
July 2026 in “Journal of Craniofacial Surgery” This study found that silencing SRD5A2 and applying melatonin significantly boosted proliferation and migration of human hair follicle stem cells without causing differentiation, while increasing MT1 expression and reducing 5-alpha-reductase levels.
July 2026 in “Journal of Dermatologic Science and Cosmetic Technology” This study found that extracts from Terminalia bellirica enhanced dermal papilla cell viability, inhibited androgen-related pathways, and stimulated hair regrowth in a mouse model, suggesting potential for treating androgenetic alopecia through multi-target mechanisms.
June 2026 in “Frontiers in Medicine” This source reports that in men treated with 5α-reductase inhibitors for androgenetic alopecia, sexual adverse events such as decreased libido and erectile dysfunction occurred at rates from 1.9% to 12% in clinical trials, with effects often being mild and reversible upon stopping treatment.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.
June 2026 in “The Journal of Sexual Medicine” This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.
June 2026 in “British Journal of Dermatology” This study reviewed human evidence on the effects of 5α-reductase inhibitors, finasteride and dutasteride, on semen parameters and gonadotrophins, finding finasteride causes mild, reversible changes, while dutasteride may lead to more pronounced and potentially less reversible impacts, suggesting caution for those planning to conceive.
May 2026 in “RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218” This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.
May 2026 in “Frontiers in Pharmacology” This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.